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In this issue of HEPATOLOGY, the article by Hu et al.
1
provides relevant information to our understanding
of the relation between coffee drinking, markers of
liver disease, and liver cancer risk.
First, it adds original data to our knowledge on the
coffee and liver disease relationship from a cohort study of
60,323 subjects who underwent seven subsequent surveys
between 1972 and 2002, and were followed-up to June
2006 (mean time of follow-up was 18 years). The study
was conducted in Finland, a country with high coffee
consumption.1 Previously available data on coffee and
liver cancer were based on at least 10 studies, six of which
were case-control (from Greece, Italy, and Japan) and
four of which were cohort investigations (all of these from
Japan). Overall, the pooled relative risk (RR) was 0.54
(95% conﬁdence interval [CI] 0.39-0.76) for case-control
studies, based on 1199 coffee drinker and 352 non–coffee
drinker cases, and 0.64 (95% CI 0.56-0.74) for cohort
studies, based on 404 coffee drinker and 305 non–coffee
drinker cases.2 All the cohort studies, however, came from
Japan, a country where coffee consumption is lower than
in western countries2 and much lower than in Finland.1
Thus, available data from cohort studies did not allow
investigation of the the dose-risk relation between coffee
and liver cancer for persons who consumed 1 cup per
day. The pooled RRs from Japanese cohort studies were
0.70 (95% CI 0.62-0.82) for 1 cup per day, and 0.50
(95% CI 0.38-0.66) for1 cup per day.
Only data from case-control studies, mainly derived
from southern Europe, allowed estimation of a pooled RR
for persons who consumed3 cups per day (RR 0.42,
95% CI 0.32-0.55,2). This estimate is largely consistent
with the RR of liver cancer for persons consuming 3
cups per day in the study by Hu et al.,1 which was around
0.4. This consistency of the results across study designs
and populations strongly supports the existence of a real
inverse relation between coffee drinking and liver cancer
risk.
A second important and original ﬁnding of the study
by Hu et al.1 is the observation that the inverse relation
between coffee and liver cancer is independent of serum
gamma-glutamyltransferase (GGT). Serum GGT levels
were available only for about 63% of cases who under-
went more recent surveys (from 1982-2002), and the RRs
for subsequent levels of coffee consumption, further ad-
justed for serum GGT, were close to those unadjusted for
that variable. The study was also able to consider the
combined effect of coffee and GGT on liver cancer risk.
Compared with heavy coffee drinkers in the three lowest
quartiles of GGT, the RR was 2.7 for those who were
nondrinkers or moderate coffee drinkers (1 cup per
day) on the same lowest quartiles of GGT, but rose to
11.0 for those in the highest quartile of GGT for non-
drinkers or moderate coffee drinkers. Given the small
number of subjects in each stratum, no CI for these esti-
mates was given, but the pattern of risk across strata is
suggestive of an independent effect of both serum GGT
and coffee drinking on subsequent liver cancer risk.
Case-control studies from Italy3-5 considered the sepa-
rate effect of coffee and the two major risk factors for liver
cancer, that is, clinical history of hepatitis or serummark-
ers for hepatitis B (HBV) and C (HCV) viruses, and al-
cohol drinking, and reported consistent inverse relations
between coffee drinking and liver cancer risk across strata
of these covariates. It is now clear, therefore, that the
inverse relation of coffee is independent from major es-
tablished risk factors for liver cancer.
Another recognized risk factor for liver cancer is to-
bacco smoking,3-5 which however tends to be directly cor-
related with coffee consumption, Furthermore, the
association between tobacco and liver cancer is much less
strong than those of HBV, HCV, and alcohol. Thus,
tobacco is unlikely to exert a relevant confounding effect
on the inverse relationship between coffee and liver can-
cer. Further, the RR provided by most studies,2-5 includ-
ing that of Hu et al.,1 were adjusted for tobacco, and if
anything, allowance for tobacco and several other vari-
ables such as education, history of diabetes, and chronic
liver disease led to a stronger inverse relation with coffee.
More important, the study by Hu et al.,1 was able to
show that the inverse relation between coffee and liver
cancer is similar across strata of smoking habits (current
smoker versus never smoked or exsmoker), as well as of
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body mass index, besides alcohol drinking, as already re-
ported by case-control studies from Italy and Greece.2-5
With reference to potential information bias, recall of
coffee drinking has been shown to be satisfactorily repro-
ducible and valid.6,7
Thus, although all observational epidemiological stud-
ies (case-control and cohort) are prone to various sources
of bias and confounding, these are unlikely to explain
such a consistent inverse association as that reported be-
tween coffee and liver cancer. Likewise, it is unlikely that
publication bias, that is, selective publication of studies
with positive ﬁndings, may account for such a strong in-
verse relation. We can now, therefore, conclude that the
inverse relation between coffee and liver cancer risk is real.
Various components of coffee, including caffeine, the
coffee oils kahweol and cafestol, antioxidant substances
from coffee beans, and chlorogenic acid, have been related
to such an inverse relation, because they may favorably
inﬂuence glucose metabolism and prevent hyperglyce-
mia,1,2,8 but no deﬁnite evidence on biologic mechanisms
of the inverse relation between coffee and liver cancer is
available.
Coffee drinking has been related to decreased levels of
liver enzymes, including GGT and alanine aminotrans-
ferase activity,8-11 and to reduced risk of type II diabetes,12
which is a recognized risk factor for liver cancer.13,14 Cof-
fee drinking has also been inversely related to the risk of
cirrhosis, with RRs around 0.2-0.3 for heavy coffee drink-
ers versus nondrinkers in studies conducted in Italy.15,16
Cirrhosis is a major correlate of hepatocellular carcino-
ma,17,18 but allowance for clinical history of cirrhosis did
not account for the inverse association between coffee and
liver cancer.8 There is therefore a continuum of clinical
and epidemiological evidence, which ranges from liver
enzymes to cirrhosis to hepatocellular carcinoma, to sup-
port a favorable effect of coffee on liver function and liver
diseases, including cirrhosis and also primary liver cancer.
Despite the apparent consistency of these ﬁndings, it is
difﬁcult to establish whether such an inverse relation be-
tween coffee and liver cancer is causal on the basis of
observational (case-control and cohort) epidemiological
studies alone. The inverse relation observed may be spu-
rious, and attributable simply to the fact that subjects with
a broad spectrum of digestive tract disorders, liver dis-
eases, or cirrhosis may reduce their coffee consumption.
Indeed, caffeine metabolism is impaired in patients with
cirrhosis, who could therefore reduce coffee intake in or-
der to avoid side effects of caffeine. Thus, bias due to
reduction of coffee drinking in unhealthy subjects cannot
be excluded.
However, in a study on hepatocellular carcinoma that
used patients with chronic liver disease as controls,19 a
reduced risk for coffee drinkers was found, similar to that
observed in studies using subjects with no liver disease as
controls. Avoidance of coffee, moreover, is not commonly
recommended to patients with chronic liver disease, and
an inverse relation between coffee and liver cancer was
also observed among subjects with self-reported2 or sero-
logical evidence of hepatitis.3,5 The study by Hu et al.8
adds relevant evidence that such an inverse relation is also
observed, and is indeed apparently stronger, in subjects in
the highest quartile of GGT, although the interaction test
between coffee consumption and serum GGT on the risk
of liver cancer was far from signiﬁcant.
Furthermore, the study by Hu et al.1 provides original
and important quantitative evidence that GGT levels are
related to subsequent incidence of liver cancer, with an
overall RR of 2.3 (95%CI 1.0-5.2). This is not surprising,
because GGT is known to be directly correlated to
chronic liver disease and cirrhosis, which is a major risk
factor and probably a pathogenic step in liver carcinogen-
esis.17,18
It remains difﬁcult, however, to translate the inverse
relation between coffee drinking and liver cancer risk ob-
served in epidemiological studies into potential implica-
tions for prevention of liver cancer by increasing coffee
consumption. Liver cancer is the third most common
cause of cancer death worldwide, with an estimated num-
ber of about 600,000 deaths per year in the early 2000s.20
Together with avoidance of lung cancer through tobacco
control, primary liver cancer is the other common neo-
plasm which is most largely avoidable, through HBV vac-
cination, control of HCV transmission, and reduction of
alcohol drinking. These three measures can, in principle,
avoid more than 90% of primary liver cancers worldwide.
Whether coffee drinking has an additional role in liver
cancer prevention remains open to discussion, but in any
case any such role would be limited—if not negligible—as
compared to that achievable through control of HBV,
HCV, and alcohol consumption, which are the major
recognized risk factors for liver cancer.
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